Abstract【Objective】To study the relationship between the levels of CD3+CD4+T cells and CD3+CD8+T cells and the prognosis of patients with advanced non-small cell lung cancer(NSCLC).【Methods】 One hundred and eighty patients with advanced NSCLC cancer were treated in our hospital. All patients received PG chemotherapy (Pemetrexed + Nedaplatin) for 2 cycles.Peripheral venous blood samples of patients after chemotherapy were collected, and the levels of T lymphocyte subsets (CD3+CD4+, CD3+CD8+) were determined . Multivariate logistic regression analysis was used to analyze the independent influencing factors of patients' short-term prognosis and to observe the relationship between the levels of CD3+CD4+, CD3+CD8+ and patients' short-term prognosis. 【Results】 After two chemotherapy cycles of 180 patients, 43 cases (23.89%) of PR and 116 cases (64.44%) of SD were found and were included in the disease control group, while 21 cases (11.67%) of PD were included in the disease uncontrolled group; the proportion of KPS score ≥ 80, tumor diameter ≥ 5cm, low differentiation, TNM stage IV, platelet count ≥ 300×109/L in the disease control group were significantly lower than those in the disease uncontrol group (P<0.05); the levels of CD3+CD4+, CD3+CD8+ were significantly higher than those of the disease uncontrol group (P<0.05). Multivariate logistic regression analysis revealed that KPS score, tumor diameter, degree of differentiation, TNM stage and extra-platelet count were independent influencing factors for the recent prognosis of patients with advanced NSCLC (P<0.05), whereas CD3+CD4+, CD3+CD8+ levels were not independent influencing factors for the recent prognosis of patients (P>0.05).【Conclusion】The recent efficacy of chemotherapy for advanced NSCLC cancer is not significantly correlated with CD3+CD4+, CD3+CD8+ levels, suggesting that detection of peripheral blood t lymphocyte subsets could not serve as a basis for judging the efficacy of chemotherapy.
2020, Vol. 37 
